United States securities and exchange commission logo





                 February 8, 2021

       Daniel Schneiderman
       Chief Financial Officer
       AzurRx BioPharma, Inc.
       1615 South Congress Avenue, Suite 103
       Delray Beach, FL 33445

                                                        Re: AzurRx BioPharma,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed February 1,
2021
                                                            File No. 333-252623

       Dear Mr. Schneiderman:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

              Please contact Jordan Metoyer at 202-551-6001 or Ada Sarmento at
202-551-3798 with
       any questions.




                 Sincerely,


                 Division of Corporation Finance

                 Office of Life Sciences
       cc:                                              James O'Grady, Esq.